Iambic Therapeutics, Inc.

Biotech San Diego, CA

About

Issuer

Entity type
Corporation
Jurisdiction
Delaware
Sector
Biotech
Headquarters
San Diego, CA
Street
5627 Oberlin Drive, Suite 120
Zip
92121

Offering

Total offering
$50M
Amount sold
$27.8M
First sale
Apr 1, 2026
Min investment
$0
Securities
Equity
Federal exemption
Rule 506(b)
Investors so far
7

How this filing compares

Ranked #4 of 47 Biotech filings in April 2026 by offering amount.

Median Biotech filing in April 2026: $3M. This offering is 16.7× the median.

Other California filings this week: A-Star Fund III, LP, Artie Technologies Inc., BAY HILLS CAPITAL PARTNERS VI-A, L.P., BAY HILLS CAPITAL PARTNERS VI, L.P., Cityview Real Estate Partners VIII, LP

Leadership

Thomas Miller — Executive Officer (also: Director)

Fred Manby — Executive Officer (also: Director)

Neil Josephson — Executive Officer

Michael Secora — Executive Officer

Jishnu Bhattacharjee — Director

Evan Rachlin — Director

R. Jacob Vogelstein — Director

Mary Tagliaferri — Director

William Rastetter — Director

Kurt von Emster — Director

Shalini Sharp — Director

Pete Olson — Executive Officer

Filing details

Iambic Therapeutics, Inc. filed a Form D with the SEC on April 8, 2026.

Other newest Biotech companies

Other newest companies in California